Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects lymphocytes, a type of white blood cell involved in the immune system. CLL often develops slowly, and some people do not need treatment immediately after diagnosis. When treatment becomes necessary, modern targeted therapies and antibody-based treatments can help control the disease, relieve symptoms, and improve long-term outcomes. Genetic testing, individualized treatment planning, and regular monitoring by a hematology team are important for managing CLL and supporting long-term outcomes.
CLL develops when abnormal B lymphocytes accumulate in the blood, bone marrow, lymph nodes, and sometimes the spleen.
The disease can vary significantly from one person to another. Some cases remain stable for many years, while others progress more quickly.
Doctors consider factors such as symptoms, blood counts, genetic characteristics, and the overall pattern of disease when determining whether treatment is needed.
Treatment is not always started immediately.
People without significant symptoms or signs of active disease may be monitored through active surveillance, sometimes called watchful waiting.
Treatment may become appropriate when there is evidence of progressive or symptomatic disease, such as:
The decision to begin treatment is individualized.
Targeted medications are an important part of modern CLL treatment.
Commonly used targeted approaches include:
Examples of targeted medicines used in CLL include ibrutinib, acalabrutinib, zanubrutinib, and venetoclax, depending on the treatment setting and individual circumstances.
Monoclonal antibodies can recognize specific proteins on leukemia cells and help the immune system eliminate them.
Examples include antibody therapies directed against CD20, such as rituximab or obinutuzumab.
These medications may be used alone or in combination with targeted treatments.
Chemotherapy was historically a major component of CLL treatment.
Although targeted therapies are now preferred in many treatment settings, chemotherapy-based regimens may still have a role in selected circumstances. Treatment decisions depend on factors such as genetic findings, previous therapy, age, overall health, and treatment goals.
Some people with difficult-to-treat or relapsed CLL may be considered for advanced treatments or clinical trials.
These may include:
Eligibility depends on disease characteristics and previous treatments.
Molecular testing is an important part of modern CLL care.
Testing may evaluate characteristics such as:
These findings can influence treatment selection and help healthcare providers estimate how the disease may behave.
CLL and its treatments can affect the immune system and increase infection risk.
Supportive care may include:
Regular blood testing helps healthcare providers monitor these issues.
Follow-up care is important throughout treatment.
Monitoring may include:
Treatment may be continued, changed, or paused depending on the individual's response.
Many people live for years with CLL while receiving ongoing monitoring or treatment.
Helpful health measures may include:
These measures complement medical treatment and ongoing hematology care.
Prompt medical evaluation is important for symptoms such as:
These symptoms may indicate infection, disease progression, anemia, or another complication.
Chronic lymphocytic leukemia treatment has changed significantly with the development of targeted therapies. Many people can be managed initially with active surveillance, while individuals with symptomatic or progressive disease may benefit from targeted medications, antibody therapy, combination approaches, or specialized treatments.